Compositions comprising nanoparticles, method of making and uses thereof
Presented herein, in certain aspects, are cell-free therapeutic composition derived from human amniotic fluid (HAF) and uses thereof for the prevention and treatment of selected diseases and disorders.
1. A therapeutic composition comprising:
(a) a modified human amniotic fluid (HAF), the modified HAF comprising particles having a particulate size of less than about 200 nm,
(b) HAF-derived nanoparticles selected from a list of nanoparticles consisting of exosomes, surface-bound proteins, and microRNAs (miRNAs);
wherein said composition is substantially free of cells, lanugo, and vernix,
wherein each of the HAF-derived nanoparticles has a diameter greater than about 30 nm, and
wherein the concentration of particles in said composition is at least about 1×10 8 particles/ml.
2. The composition of claim 1 , wherein the concentration of particles in said composition is at least about 1×10 9 particles/ml.
3. The composition of claim 2 , wherein the concentration of particles in said composition is at least about 1×10 11 particles/ml.
4. The composition of claim 3 , wherein the concentration of particles in said composition is in a range of about 2×10 11 particles/ml to about 1.1×10 12 particles/ml.
5. The composition of claim 1 , wherein each of the HAF-derived nanoparticles have a diameter in a range of about 50 nm to about 250 nm.
6. The composition of claim 5 , wherein each of the HAF-derived nanoparticles is less than about 1000 nm in size.
7. The composition of claim 1 , wherein the HAF-derived nanoparticles comprise membrane encapsulated extracellular vesicles.
8. The composition of claim 1 , wherein the HAF-derived nanoparticles comprise surface-bound protein CD63.
9. The composition of claim 8 , wherein said composition comprises CD63 at a concentration of at least about 10 μg/ml.
10. The composition of claim 1 , wherein the HAF-derived nanoparticles comprise three or more surface-bound proteins selected from a group consisting of CD9, CD63, CD81, CD326 and CD133.
11. The composition of claim 10 , wherein the HAF-derived nanoparticles further comprise two or more surface-bound proteins selected from CD14, CD24, CD42a, CD44, CD29, CD14 and CD146.
12. The composition of claim 11 , wherein the HAF-derived nanoparticles further comprise surface bound proteins HLA-DR, HLA-DP and HLA-DQ.
13. The composition of claim 1 , wherein the HAF-derived nanoparticles comprise at least one miRNA selected from Table 1.
14. The composition of claim 13 , wherein the HAF-derived nanoparticles comprise five or more miRNAs selected from hsa-let-7b, hsa-mir-200c, hsa-mir-30d, hsa-mir-125a, hsa-mir-483, hsa-mir-34c, hsa-mir-200a, hsa-mir-148a, hsa-mir-191, hsa-mir-21, hsa-mir-146a, hsa-mir-26b, hsa-mir-92b, hsa-mir-342, hsa-mir-34b, hsa-mir-423, hsa-mir-205, hsa-mir-203a, hsa-mir-99b, hsa-mir-375, hsa-mir-10b, hsa-mir-449c, hsa-mir-320a, and hsa-let-7f-2.
15. The composition of claim 13 , wherein the HAF-derived nanoparticles comprise ten or more miRNAs selected from hsa-let-7b, hsa-mir-200c, hsa-mir-30d, hsa-mir-125a, hsa-mir-483, hsa-mir-34c, hsa-mir-200a, hsa-mir-148a, hsa-mir-191, hsa-mir-21, hsa-mir-146a, hsa-mir-26b, hsa-mir-92b, hsa-mir-342, hsa-mir-34b, hsa-mir-423, hsa-mir-205, hsa-mir-203a, hsa-mir-99b, hsa-mir-375, hsa-mir-10b, hsa-mir-449c, hsa-mir-320a, hsa-let-7f-2, hsa-mir-23a, hsa-mir-27b, hsa-mir-93, hsa-mir-221, hsa-mir-425, hsa-mir-151a, hsa-mir-190b, hsa-mir-223, hsa-mir-1180, hsa-mir-184, hsa-mir-361, hsa-mir-182, hsa-mir-92a-1, hsa-mir-29a, hsa-mir-183, hsa-mir-204, hsa-mir-574, hsa-mir-532, hsa-mir-28, hsa-mir-744, hsa-mir-2110, hsa-mir-140, hsa-mir-1307, hsa-mir-193b, hsa-mir-660, hsa-mir-224, hsa-mir-196b, hsa-mir-339, hsa-mir-186, hsa-mir-3065, hsa-mir-378a, hsa-mir-16-1, hsa-mir-338, hsa-mir-126, hsa-mir-95, hsa-mir-142, hsa-mir-328, hsa-mir-335, hsa-mir-125b-2, hsa-mir-149, and hsa-mir-150.
16. The composition of claim 1 , wherein the HAF-derived nanoparticles comprise hsa-mir-30d, hsa-mir-191, hsa-mir-21, and hsa-mir-146a.
17. The composition of claim 1 , wherein the HAF-derived nanoparticles comprise two or more miRNAs selected from hsa-mir-30d, hsa-mir-191, hsa-mir-21, and hsa-mir-146a.
18. The composition of claim 1 , wherein the HAF-derived nanoparticles comprise DNA polymerase beta, DNA polymerase lambda, telomerase reverse transcriptase, and RAD50.
19. The composition of claim 1 , wherein said composition comprises hyaluronic acid at a concentration of at least about 200 ng/ml.
20. The composition of claim 19 , wherein said composition comprises hyaluronic acid at a concentration of about 200 ng/ml to about 2000 ng/ml.
21. The composition of claim 19 , wherein said composition comprises hyaluronic acid at a concentration of about 600 ng/ml to about 2000 ng/ml.
22. The composition of claim 1 , wherein said composition is substantially free of bacteria, fungus and yeast.
23. The composition of claim 1 , wherein said composition comprises at least one cytokine or growth factor selected from a group consisting of angiogenin (ANG), BLC, EGF, FGF-6, GCP-2, IGFBP-1, IGF-BP2, IGF-BP4, IL-1RA, IL-6, LEPTIN, MCP-1, MIG, MIP-1DELTA, NAP-2, adiponectin (ACRP30), GRO-A, HCC-4, HGF, ICAM-1, IGFBP-6, IL-1R4, IL-6R, IL-8, OPG, STNFRII, STNFRI, TIMP-1, TIMP-2, and UPAR.
24. The composition of claim 23 , wherein said composition comprises ANG, IL-1RA, MCP-1, IL-6, UPAR, FGF-6, EGF, HGF, LEPTIN, and ACRP30.
25. The composition of claim 1 , wherein said composition comprises at least one of ACRP30, AGRP, ANGPT2, AREG, AXL, B-NGF, BFGF, BTC, CCL28, CTAK, DTK, EGFR, ENA-78, FAS, FGF-4, FGF-9, G-CSF, GITR, GITR LIGAND, GRO, GRO-ALPHA, HCC-4, HGF, I-TAC, ICAM-1, ICAM-3, IGF-1SR, IGFBP-3, IGFBP-6, IL-11, IL-12 P40, IL-12 P70, IL-17, IL-1R1, IL-2R ALPHA, IL-6R, IL-8, IL1R4, MIF, MIP-1 ALPHA, MIP-2 BETA, MIP-3 BETA, MSP ALPHA, NT-4, OPG, OSM, PLGF, SGP130, STNFRI, STNFRII, TECK, THPO, TIMP-1, TIMP-2, TRAIL R3, TRAIL R4, UPAR, VEGF, VEGF-D, XCL1, ANG, BDNF, BLC, BMP4, BMP6, CCL23, CNTP, EGF, Eoxtanin 1, Eoxtanin 2, Eoxtaxin 3, FGF-6, FGF-7, FLT3-LIGAND, FRACTALKINE, GCP-2, GDNF, GMCSF, 1-309, IGF-1, IGFBP1, IGFBP2, IGFBP4, IL-10, IL-13, IL-15, IL-16, IL-1B, IL-1RA, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL1-A, INF GAMMA, LEPTIN, LIGHT, M-CSF, MCP-1, MCP-2, MCP-3, MCP4, MDC, MIG, MIP-1A, MIP-3A, NAP-2, NT-3, PARC, PDGFBB, RANTES, SCF, SDFIA, TARC, TGF-B1, TGF-B3, TNFA, and TNFB.
26. The composition of claim 1 , wherein the at least one nanoparticle comprises CD9+ and CD63+ at a concentration of at least about 10 μg/ml.
27. The composition of claim 1 , wherein the at least one nanoparticle comprises CD9+ and CD63+ at a concentration of at least about 200 μg/ml.
28. The composition of claim 1 , wherein the at least one nanoparticle comprises CD9+ and CD63+ at a concentration of at least about 1000 μg/ml.
29. The composition of claim 1 , wherein said composition suppresses t-cell activation and proliferation, macrophage migration, and human inflammatory responses.
30. A pharmaceutical composition comprising:
(i) a modified human amniotic fluid (HAF), the modified HAF having a particulate size of less than about 200 nm and having an amount of HAF; and
(ii) HAF-derived nanoparticles, the HAF-derived nanoparticles comprising at least one nanoparticle selected from a list of nanoparticles comprising exosomes, surface-bound proteins, and microRNAs (miRNAs);
wherein said composition is substantially free of cells, lanugo, and vernix,
wherein each of the HAF-derived nanoparticles has a diameter greater than about 30 nm,
wherein the concentration of particles in said composition is at least about 1×10 9 particles/ml, and
(iii) one or more pharmaceutically acceptable ingredients, the one or more pharmaceutically acceptable ingredients comprising excipients and additives.
31. The pharmaceutical composition of claim 30 , wherein said pharmaceutical composition is configured for administration via one or more methods of administration, the one or more methods of administration including oral administration, parenteral administration, administration via nebulization, and intravenous administration.
32. A method of treating a lung disease or lung disorder in a subject in need thereof, comprising administering an effective amount of the therapeutic composition of claim 1 to the subject, wherein the disease or disorder is selected from acute respiratory syndrome, chronic obstructive pulmonary disease (COPD) and bronchopulmonary dysplasia.
33. The method of claim 32 , wherein the lung disease or lung disorder comprises chronic obstructive pulmonary disease (COPD).
34. The method of claim 32 , wherein the lung disease or lung disorder comprises bronchopulmonary dysplasia (BPD).
35. The method of claim 32 , wherein the lung disease or lung disorder comprises acute respiratory syndrome.
36. The method of claim 35 , wherein the subject is infected with a coronavirus.
37. The method of claim 36 , wherein the subject is infected with a COVID19 or SARS-associated coronavirus (SARS-COV2).
38. A method of treating acute brain injury in a subject in need thereof, comprising administering to the subject an effective amount of the composition of claim 1 .
39. A method of treating acute organ failure in a subject in need thereof, comprising administering to the subject an effective amount of the composition of claim 1 .
40. A method of treating arthritis in a subject in need thereof, comprising administering to the subject an effective amount of the composition of claim 1 .
41. The method of claim 40 , wherein the arthritis is osteoarthritis or rheumatoid arthritis.
42. The method of claim 40 , wherein the composition is administered by intravenous or intraarticular injection.
43. The method of claim 40 , wherein the subject is human.